RE:28 of aprilMyKnight]Being out of the loop, what is going on for the 28 april..
whisky11: my bad it's just some kind of record date
The Company also announced today that it is holding its annual and special meeting of shareholders on June 17, 2021 (together with any adjournment or postponement thereof, the “Meeting”). The record date for the Meeting is April 28, 2021. Only shareholders of record at the close of business on April 28, 2021, may vote at the Meeting. The Company’s proxy statement will be sent to shareholders of record and will describe the matters to be voted upon. Only shareholders of record at the close of business on April 6, 2021, may vote at the meeting. The Company’s proxy statement will be sent to shareholders of record and will describe the matters to be voted upon. The Meeting will begin at 9:00 a.m. Pacific Time and will include an update on the Company’s operations and business strategy. For the convenience of shareholders, shareholders may view the Meeting live via a webcast. The link for the webcast will be included in shareholder materials, and will also be posted on the Company’s website in the investors section.
At the Meeting, shareholders will be asked to vote on the election of directors; the appointment of the Company’s auditors; and the renewal of the Company’s rolling 10% stock option plan. Shareholders will also be asked to consider and vote on a resolution that would approve a special resolution authorizing the Company to transfer and sell to the former shareholders of Talent Biotechs Ltd. (the “Former Shareholders”) all assets of the Company’s program developing cannabidiol for the prevention and treatment of graft versus host disease (the “GVHD Program”) in consideration for the release and discharge by the Former Shareholders of all obligations the Company and its subsidiaries have to such Former Shareholders. In addition, shareholders will also be asked to consider and vote on a resolution that would authorize the board of directors of the Company (the “Board”) to implement, at a later date, a potential consolidation (the “Potential Consolidation”) of the Company’s common shares (the “Common Shares”) on the basis of a ratio of one post-consolidation Common Share to up to 20 pre-consolidation Common Shares (or a lower number of pre-consolidation Common Shares as may be determined by the Board).
The Company is seeking authority to complete a Potential Consolidation at a later date if and when it is in the best interests of the Company to do so, but the Board has not made a decision to implement a Potential Consolidation at this time. Even if the Potential Consolidation is approved by shareholders at the Meeting the Board will have the discretion to not proceed with the Potential Consolidation. If the Board decides to proceed with the Potential Consolidation, the purpose for doing so would be to generate interest in the Company among certain investors, to comply with the pricing policies of the TSX Venture Exchange (the “TSXV”), to improve the trading liquidity of the Common Shares and to reduce volatility in the price of the Common Shares.
In addition to shareholder approval, the Potential Consolidation is subject to the approval of the TSXV. If the Potential Consolidation were to be implemented today at the maximum authorized consolidation ratio, the 571,027,592 currently issued and outstanding Common Shares would be consolidated into 28,551,380 Common Shares. Additional information on the Potential Consolidation, and the risks associated therewith, can be found in the management information circular of the Company that will be sent to Claritas shareholders in connection with the Meeting and will be available on the Company’s SEDAR profile